Snowed-Out Sarepta Panel Likely Delays FDA Verdict
This article was originally published in Scrip
With a major winter snowstorm that's expected to slam the Washington area – snarling traffic, delaying airline flights and wreaking havoc in general – the FDA decided to postpone the highly anticipated Jan. 22 meeting of the agency's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee, although regulators gave panelists, patient advocates and others planning to attend the hearing little warning ahead of time.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.